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Abstract
Background:  Familial Juvenile Hyperuricemic Nephropathy is an autosomal dominant
nephropathy, characterized by decreased urate excretion and progressive interstitial nephritis.
Mutations in the uromodulin coding UMOD gene have been found responsible for the disease in
some families.
Case presentation: We here describe a novel heterozygous p.K307T mutation in an affected
female with hyperuricemia, renal cysts and renal failure. The proband's only son is also affected and
the mutation was found to segregate with the disease.
Conclusions: This mutation is the fourth reported in exon 5. Initial studies identified a mutation
clustering in exon 4 and it has been recommended that sequencing this exon alone should be the
first diagnostic test in patients with chronic interstitial nephritis with gout or hyperuricemia.
However, regarding the increasing number of mutations being reported in exon 5, we now suggest
that sequencing exon 5 should also be performed.
Background
Familial Juvenile Hyperuricemic Nephropathy (FJHN)
(McKusick 162000) is an autosomal dominant disorder
characterized by hyperuricemia, decreased urinary excre-
tion of urate and the development of progressive chronic
interstitial nephritis. Renal impairment usually appears
between 15 and 40 years of age, leading to end-stage renal
disease (ESRD) within 10 to 20 years [1]. A candidate gene
for FJHN has been positioned in 16p11.2-12, together
with evidence for genetic heterogeneity [2,3]. The candi-
date gene was later found to map within the same genetic
interval as MCKD2, a locus responsible for medullary
cystic kidney disease, therefore suggesting that FJHN and
MCKD2 are 2 facets of the same disease [1]. The marked
thickening of tubular basement membranes observed in
FJHN closely resembles the renal histological findings of
the nephronophthisis-medullary cystic kidney disease
complex (NPH-MCKD). Diseases of this group share the
macroscopic feature of cyst development at the corti-
comedullary border of the kidney and the renal histologi-
cal triad of tubular basement membrane disintegration,
tubular atrophy with cyst development and interstitial cell
infiltration with fibrosis [4]. Within this complex, clinical
entities can be distinguished based on the mode of inher-
itance, the age of onset for ESRD and the presence of extra-
renal involvement. For the recessive forms of the disease 4
different genes have been cloned. The NPHP1 gene [5,6]
and NPHP4 [7] are responsible for juvenile forms of NPH,
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while NPHP2 [8] and NPHP3 [9] account for, respec-
tively, the infantile and adolescent forms. MCKD, the
autosomal dominant disorder that presents in early adult-
hood, is usually accompanied by the detection of corti-
comedullary cysts on imaging studies. MCKD1 maps to
1q21 and remains to be cloned, while MCKD2 has been
positioned in 16p12. Mutations in the uromodulin/
Tamm-Horsfall protein coding UMOD gene located
within the critical interval of FJHN and MCKD2 at
16p11.2-12 were recently identified in FJHN and MCKD2
families [10], therefore providing definite evidence that
MCKD and FJHN are allelic disorders. Meanwhile, a
mutation cluster in exon 4 of UMOD was reported for
both diseases [11,12].
We here describe a novel heterozygous missense mutation
in affected individuals from a Portuguese FJHN family
that also displays corticomedullary cysts on ultrasound
examination. This mutation, c.920A→C, resides in exon 5
and is the fourth reported outside exon 4.
Case presentation
Case report
The proband is an affected female who was first evaluated
at the age of 24, when she presented with a gout attack
and hyperuricemia. At age 27 she was told having renal
failure. However, a renal biopsy was not performed. At age
44, serum creatinine was 2.8 mg/dl and ultrasound imag-
ing detected numerous renal cysts. Renal disease slowly
progressed and the patient reached ESRD when she was
49 years old. Her father died at the age of 55 from ESRD
and suffered from hyperuricemia and gout. The proband's
only son is also affected. At the age of 18 years he had a
gout attack. On the initial evaluation, serum uric acid was
15 mg/dl and serum creatinine 1.6 mg/dl. Renal cysts
were also detected on ultrasound examination.
Mutation analysis
Informed consent was obtained from tested individuals.
Genomic DNA was isolated from peripheral blood leuco-
cytes and the coding region of the UMOD gene was
screened for mutations by direct sequencing of PCR prod-
ucts. We used a set of primers previously described [10]
except in exons 4 and 5, for which different additional
internal sequencing primer were designed based upon
sequences from GenBank (accession numbers
NT_024776.6 and M17778).
Results
A novel heterozygous missense mutation, c.920A→C, was
detected (Figure 1) and found to segregate with the dis-
ease in this family. The mutation results in a Lys to Thr at
a) Sequence of the index patient with exon 5 c.920A→C heterozygous missense mutation Figure 1
a) Sequence of the index patient with exon 5 c.920A→C heterozygous missense mutation. b) The same mutation sequenced 
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position 307. This mutation was not detected in any of the
100 control chromosomes tested. In fact, no polymor-
phism affecting the translation of uromodulin was
detected in 100 control chromosomes in a previous report
[10] and we are, therefore, excluding the possibility of this
allele being a mere polymorphism. In addition, the
affected mother was found to be homozygous for the T
allele in the common T to C transition synonymous poly-
morphism at codon C174.
Discussion
The UMOD gene has 12 exons and codes for the 640
amino-acid uromodulin, a glycsoyl phosphatidylinositol
(GPI) anchored protein that accounts for the primary
structure of the 85-kD Tamm-Horsfall glycoprotein
(THP). THP is the most abundant protein in the urine
and, in normal kidney, uromodulin expression is
restricted to the thick ascending limb (TAL) and distal
convoluted tubule. Urinary excretion occurs by proteo-
lytic cleavage of the GPI counterpart at the luminal surface
of TAL. It has been suggested that one of THP major role
is of an urinary anti-adherence factor preventing type 1
fimbriated E coli from binding to the urothelial receptors
[13].
The majority of the mutations so far published are clus-
tered in exon 4, between codons 52 and 282, and most are
missense mutations affecting cysteine residues (Table 1).
Exon 4 contains 3 calcium binding epidermal growth fac-
tor (cbEGF)-like domains, between residues 31 and 148.
A fourth potential cbEGF-like domain extends from
amino-acids 281–336, throughout exon 5. They contain 6
conserved cysteine residues responsible for the protein's
tertiary structure, as a result of intramolecular disulfide
bonding. It has been hypothesized that protein misfold-
ing, consequence of mutations in these cbEGF-like
domains, may affect uromodulin intracellular trafficking
and lead to cellular protein accumulation and apoptosis
[14]. The release of cells debris and uromodulin aggre-
gates in the interstitium could stimulate an inflammatory
response and, in addition, be responsible for tubular
obstruction and medullary cyst formation. It has been
proposed that hyperuricemia in these patients is second-
ary to a reduced TAL sodium reabsorption with volume
contraction and a compensatory increase in proximal
urate reabsorption. The role of hyperuricemia in the
chronic interstitial nephritis remains to be clarified, since
the deposition of sodium urate crystals in the medullary
interstitium does not occur in these patients. The muta-
tion c.920A→C here reported, replaces the basic amino-
acid Lys for the uncharged polar Thr at position 307
(p.K307T), being the fourth mutation described in exon 5.
The affected residue locates within the fourth cbEGF-like
domain and is immediately preceded by a highly con-
served cysteine residue.
Conclusions
It has been referred that exon 4 sequencing should
become the first diagnostic test in patients with chronic
interstitial nephritis with gout or hyperuricemia, even in
the absence of a family history [11]. In view of the increas-
ing number of mutations in exon 5 being identified, we
now recommend that exon 5 should be included in the
initial sequencing effort, since otherwise nearly 12% of
UMOD mutations can be missed.
Competing interests
The author(s) declare that they have no competing
interests.
Table 1: UMOD mutations reported in the literature.
Mutation exon reference
c.156T→G; p.C52W 4 [15]
c.176A→C; p.D59A 4 [11]
c.230G→A; p.C77Y 4 [16]
c.278_289del/insCCGGCTCCT; 
p.V93_G97del/insAASC
4[ 1 2 ]
c.307G→T; p.G103C 4 [10]
c.334T→C; p.C112R 4 [11]
c.376T→C; p.C126R 4 [16]
c.383A→G; p.N128S 4 [16]
c.403T→A; p.C135S 4 [15]
c.443G→A; p.C148Y 4 [10]
c.444T→G; p.C148W 4 [14]
c.449G→C; p.C150S 4 [14]
c.509G→A; p.C170Y 4 [11]
c.529_555del; p.H177_R185del 4 [10]
c.553C→G; p.R185G 4 [18]
c.553C→A; p.R185S 4 [11]
c.563_661del; p.E188_L221del 4 [11]
c.584G→T; p.C195F 4 [15]
c.605G→C; p.W202S 4 [15]
c.610C→G; p.R204G 4 [11]
c.649T→C; p.C217R 4 [10]
c.649T→G; p.C217G 4 [11]
c.665G→C; p.R222P 4 [11]
c.668G→A; p.C223Y 4 [17]
c.674C→T; p.T225M 4 [11]
c.674C→A; p.T225K 4 [12]
c.707C→T; p.P236L 4 [15]
c.744C→G; p.C248W 4 [12]
c.764G→A; p.C255Y 4 [16]
c.844T→C; p.C282R 4 [11]
c.898T→G; p.C300G 5 [16]
c.920A→C; p.K307T 5 present report
c.943T→C; p.C315R 5 [14]
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